Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.
- DOI
- 10.1093/oncolo/oyag330
- Published
- 2026 Aug 6
- Container
- The oncologist
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/oncolo/oyag330,
title = {Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.},
author = {Okines AFC and Roesch E and Watkins K and Pitner MK and Hutchinson KM and Simon S and Yan F},
year = {2026},
journal = {The oncologist},
doi = {10.1093/oncolo/oyag330},
url = {https://doi.org/10.1093/oncolo/oyag330}
}RIS
TY - JOUR TI - Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine. AU - Okines AFC AU - Roesch E AU - Watkins K AU - Pitner MK AU - Hutchinson KM AU - Simon S AU - Yan F PY - 2026 JO - The oncologist DO - 10.1093/oncolo/oyag330 UR - https://doi.org/10.1093/oncolo/oyag330 ER -
APA
AFC, O., E, R., K, W., MK, P., KM, H., S, S., & F, Y. (2026). Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.. The oncologist. https://doi.org/10.1093/oncolo/oyag330
Source records
- pubmed · retrieved 2026-09-26T10:27:23.430Z